Value Investor
Start free

Intellia Therapeutics

NTLA on Nasdaq. Intellia Therapeutics makes gene editing medicines for patients with severe diseases. Market value $1.8bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-20.1%low

For every $100 of what the whole company costs, it produced $-20.12 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-50.8%five-year median

Each dollar kept in the business earns -51 cents a year. Above 10 is good.

Quality score: 32 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$12.37 a share, 56% above its 1-year low

Over the past year the price has ranged from $7.95 to $28.25.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.2
-0.3
-0.4
-0.4
-0.4
-0.3
2021202220232024202512 monthsto Jun '26
Revenue
$33m$52m$36m$58m$68m
Operating margin
-810.4%-879.0%-1420.5%-923.1%-651.7%
Debt to equity
0.000.000.000.000.00
Shares outstanding
0.08bn0.09bn0.10bn0.12bn0.14bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • Debt0.00× equity
  • Revenue growth, five yearsSlow, 3.1% a year
  • Buying back its own sharesNo, 78% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $8 million last quarter, down 46% on a year ago.
  • A loss of $107 million, compared with a loss of $101 million a year ago.
  • It loses 712 cents on each $1 of sales, compared with 969 cents a year earlier.
  • Over the past 12 months it spent $349 million more cash than it brought in, compared with $422 million a year earlier.
  • 29% more shares than a year ago. Each share owns a bit less of the company.
  • It has $106 million more cash than debt, down from $156 million a year ago.
  • Sales grew on a year ago in 2 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$9m
December 2024$13m
March 2025$17m
June 2025$14m
September 2025$14m
December 2025$23m
March 2026$15m
June 2026$8m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$136m
December 2024-$129m
March 2025-$114m
June 2025-$101m
September 2025-$101m
December 2025-$96m
March 2026-$96m
June 2026-$107m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
26 February 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 328 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $1m of shares on the open market. 7 sold $2m, $1m of it under preset trading plans.

  • Dube Michael P
    VP, Chief Accounting Officer
    Sold
    Date
    2 October 2026
    Shares
    1,864
    Price
    $12.43
    Value
    $23,170
  • LEONARD JOHN M
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    21 August 2026
    Shares
    2,785
    Price
    $13.00
    Value
    $36,205
  • LEONARD JOHN M
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    20 August 2026
    Shares
    19,890
    Price
    $12.60
    Value
    $250,614
  • Dulac Edward J III
    EVP, Chief Financial Officer
    Sold
    Date
    22 July 2026
    Shares
    8,111
    Price
    $11.25
    Value
    $91,249
  • Dulac Edward J III
    EVP, Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    2 July 2026
    Shares
    4,677
    Price
    $18.00
    Value
    $84,186
  • Dube Michael P
    VP, Chief Accounting Officer
    Sold
    Date
    1 July 2026
    Shares
    2,641
    Price
    $16.78
    Value
    $44,316
  • BASTA JAMES
    EVP, General Counsel
    Sold
    Date
    2 March 2026
    Shares
    1,211
    Price
    $13.78
    Value
    $16,688
  • Clark Eliana
    EVP, Chief Technical Officer
    Sold
    Date
    2 March 2026
    Shares
    607
    Price
    $13.78
    Value
    $8,364
  • LEONARD JOHN M
    President and CEO, Director
    Sold
    Date
    5 January 2026
    Shares
    34,146
    Price
    $9.21
    Value
    $314,485
  • Schultes Birgit C
    EVP, Chief Scientific Officer
    Sold
    Date
    5 January 2026
    Shares
    8,508
    Price
    $9.21
    Value
    $78,359

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 6 Aug 2026 and 10 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.